Last reviewed · How we verify
NCT06154382
Eltroxin Administration to Patients With Extremely Low T4 Values in the Intensive Care Unit
trial testing Eltroxin administration in Thyroid; Functional Disturbance in 350 participants. Currently enrolling.
1 February 2026
Quick facts
| Lead sponsor | Meir Medical Center |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 350 |
| Start date | 1 June 2024 |
| Primary completion | 1 February 2026 |
| Estimated completion | 1 February 2026 |
| Sites | 1 location across Israel |
Drugs / interventions tested
- Eltroxin administration — full drug profile →
Conditions studied
- Thyroid; Functional Disturbance — all drugs for Thyroid; Functional Disturbance →
Sponsor
Meir Medical Center
Who can join
Adults 18 to 99, any sex, with Thyroid; Functional Disturbance. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Nonthyroidal illness (formerly called sick euthyroid syndrome) is a common condition in patients hospitalized in the intensive care unit, and it is caused by changes in the levels of thyroid hormones in the blood . These changes are correlated to the severity of the critical illness, morbidity and mortality. This condition is characterized by low serum T3 levels, high rT3 levels, normal or low T4 levels, and normal or low TSH levels. Previous studies have shown a relationship between NTIS (nonthyroidal illness) and poor therapeutic outcomes in patients admitted with sepsis, multi trauma, ARDS, acute respiratory failure, septic shock and mechanically ventilated patients in intensive care . In general, the recommendation is not to routinely take blood tests to evaluate thyroid function in critical patients in the intensive care unit, unless they were previously known to have a thyroid disease or there is a clinical suspicion that such a disorder developed during hospitalization in the intensive care unit. Also, studies so far have not shown an advantage for eltroxin administration to intensive care patients with low T3 and/or T4 levels when the laboratory tests indicate NTIS. However, there is a specific group of patients, with NTIS and extremely low T4 levels (less than 50% of the lower limit of the normal range) who have a particularly high mortality rate in intensive care (over 85%) and in whom it has not been investigated whether the administration of eltroxin will improve the therapeutic outcomes ( , i.e. was such a low T4 level in them considered a marker for the severity of their general critical illness, or is it another disorder in itself, the treatment of which would benefit the patient) . We would like to examine whether the administration of eltroxin in this specific group of patients, which has not been studied so far, will be beneficial in improving the therapeutic outcomes
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06154382
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Thyroid; Functional Disturbance
Currently open trials in the same condition.
- NCT03977207 — A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis Patients · NA · recruiting
- NCT06418919 — A Prospective Evaluation of Radiofrequency Ablation in the Treatment of Relapsed Graves' Disease. · NA · active not recruiting
Other Meir Medical Center trials
Trials by the same sponsor.
- NCT07256886 — Validation of the iCVS Model in Patients Admitted to the Intensive Care Unit · not yet recruiting
- NCT07315477 — Characteristics of Patients Intubated for Airway Protection in the Intensive Care Unit and Timing of Tracheostomy · not yet recruiting
- NCT07183410 — Impact of Blood Cultures Drawn From Arterial Lines on the Incidence of Contamination, Detection of Bacteremia, and Blood · not yet recruiting
- NCT07256860 — Influence of Chest X-ray vs. Chest CT Scan on the Management of ICU Patients With Respiratory Failure · not yet recruiting
- NCT05784350 — Preoperative Point of Care Ultrasound Guided Fluid Optimization and Intravenous Ondansetron to Prevent General Anesthesi · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06154382 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Meir Medical Center
- Last refreshed: 11 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06154382.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing